What are the contraindications when using mivamutide? Which patients are not suitable for this drug?

Mifamurtide (Mifamurtide), as an immunomodulatory drug, is mainly used to treat osteosarcoma, especially patients with a high risk of postoperative recurrence. However, although mivamutide has significant therapeutic benefits for many patients, not everyone is a candidate for the drug. The following are some common contraindications and patient groups for which mivamutide is inappropriate.

1. History of allergic reaction: Patients with a history of allergy to mivamutide or its components Absolutely should not use this drug. If the patient has allergic reactions (such as rash, difficulty breathing, facial swelling, etc.) before using miavamuttide or during treatment, he should stop using it immediately and seek emergency treatment. Anaphylaxis is a potential risk during treatment with mivamutide, so patients with a history of allergies should avoid using this drug.

2. Patients with severe hepatic and renal impairment: The metabolism and excretion of mivamutide in the body involves liver and renal function, therefore, patients with severe liver or renal impairment should avoid using this drug. For patients with hepatitis, liver failure or chronic kidney disease , mivamutide may worsen the symptoms of these underlying diseases and increase the risks of treatment. Therefore, before starting to use mivamutide, patients need to evaluate the safety of its use through liver and renal function tests .

3. Patients with abnormal immune system function: Milvage peptide exerts anti-tumor effects by activating the patient's immune system and enhances the functions of natural killer cells and macrophages . Therefore, patients with abnormal immune system function (such as patients with autoimmune diseases or immunodeficiencies) may not be able to withstand the immune activation caused by drugs, increasing the risk of immune-related adverse reactions. Such patients need to avoid using mivamutide or use it under close supervision by a doctor.

4. Pregnant and lactating women: The safety of mivamutide has not been fully confirmed in pregnant and lactating women. Because of the potential negative effects drugs may have on the fetus or infant, pregnant and breastfeeding women Mivarintide should be avoided. If the patient is pregnant or planning to become pregnant, the patient should inform the doctor so that the doctor can choose an appropriate treatment plan.

In summary, although mivamutide is an effective therapeutic drug, it is not suitable for certain patient groups due to its ability to activate the immune system and its potential impact on liver and kidney function. Before starting treatment, patients should discuss their medical history in detail with their doctor to ensure the safe use of mivamutide.

xa0

References: https://pubmed.ncbi.nlm.nih.gov/23997016/